Stockscreener 앱 받기
0.718
41.03%
-0.452
Brainstorm Cell Therapeutics Inc 주식(BCLI)의 최신 뉴스
What analysts say about Brainstorm Cell Therapeutics Inc. stockSuperior risk-adjusted returns - PrintWeekIndia
What drives Brainstorm Cell Therapeutics Inc. stock priceRapid capital growth - PrintWeekIndia
What risks could impact Brainstorm Cell Therapeutics Inc. stock performanceMarket-beating performance - jammulinksnews.com
Is Brainstorm Cell Therapeutics Inc. a good long term investmentFree Stock Selection - PrintWeekIndia
How Brainstorm Cell Therapeutics Inc. stock reacts to Fed policy changesAccelerated financial growth - jammulinksnews.com
BrainStorm Cell Therapeutics Downgraded to Hold by Maxim Group - AInvest
Maxim Group Downgrades Brainstorm Cell Therapeutics(BCLI.US) to Hold Rating, Raises Target Price to $6.6 - 富途牛牛
Brainstorm Cell Therapeutics Inc. Stock Analysis and ForecastFree Stock Market Knowledge Sharing - jammulinksnews.com
BrainStorm Cell Therapeutics to move from Nasdaq to OTCQB after delisting; shares down - MSN
INVESTOR ALERT: Levi & Korsinsky Reminds Brainstorm Cell Therapeutics Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024BCLI - ACCESS Newswire
BrainStorm Cell Therapeutics Crashes After Hours On Nasdaq Delisting Notice; Retail Sees 'Buy Time' - Stocktwits
Brainstorm Cell Therapeutics Crashes 42% After Voluntary Nasdaq Delisting Announcement - inkl
Brainstorm Cell Therapeutics Announces Nasdaq Delisting And Transition To Otcqb - TradingView
Brainstorm Cell Therapeutics Faces Nasdaq Delisting Notice - TipRanks
Brainstorm Cell Therapeutics to Delist From Nasdaq - MarketScreener
BrainStorm Cell Therapeutics shares fall 51.20% after-hours after Nasdaq delisting notification. - AInvest
BrainStorm Cell Therapeutics stock delisted from Nasdaq, trades on OTCQB - AInvest
BrainStorm Cell Therapeutics to delist from Nasdaq, move to OTCQB By Investing.com - Investing.com India
BrainStorm Cell Therapeutics to delist from Nasdaq, move to OTCQB - Investing.com
BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB - WV News
BrainStorm Receives 3 Million NIS Grant from Israel's Office of the Chief Scientist - AOL.com
Why Brainstorm Cell Therapeutics Inc. stock attracts strong analyst attentionFree Deep Market Trend Analysis - Newser
What makes Brainstorm Cell Therapeutics Inc. stock price move sharplyFree Stock Trading Community - Newser
How Brainstorm Cell Therapeutics Inc. stock performs during market volatilityFree Access to Community with 300% Return - Newser
FDA to review citizen petition on BrainStorm’s ALS therapy NurOwn By Investing.com - Investing.com South Africa
ALS Community Petitions FDA To Reconsider BrainStorm’s NurOwn, Pointing to Recent Survival Data - BioSpace
BTCS, BrainStorm Cell, Moderna - TradingView
FDA Review of Citizen Petition Offers a Fresh Look at NurOwn®'s Evidence of Treatment Effectiveness - The Malaysian Reserve
BrainStorm Cell Therapeutics: A Rare Disease Breakthrough on the Brink of Regulatory Approval - AInvest
NurOwn's Regulatory Crossroads: Why BrainStorm Cell Therapeutics (BCLI) Could Be Poised for a Turnaround - AInvest
FDA to review citizen petition on BrainStorm’s ALS therapy NurOwn - Investing.com
BCLI: Citizen's Petition Filed Requesting the FDA Approve NurOwn - Smartkarma
ALS Community Files Citizens’ Petition asking FDA to Approve NurOwn Stem Cell Therapy - Asbury Park Press
0.97%
0.22%
자본화:
|
볼륨(24시간):